NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MindWalk Holdings Corp. (HYFT) Stock Analysis

MindWalk Holdings Corp. (HYFT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HYFT

$1.32

−$0.01 (−0.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HYFT with… →

HYFT Key Statistics

As of Sep 4, 2026
Trading
Open
$1.31
Previous Close
$1.33
Day's Range
1.30–1.39
52-Week Range
0.99–2.99
Volume
91.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.83
Valuation
Market Cap
$62.02M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.24
Financials (FY)
Revenue (FY)
$15.56M+46.41%
Net Income (FY)
−$13.95M
Profit marginThe share of revenue left as profit after all costs and taxes.
−89.66%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
46.99M
1-Year Return
−33.67%
Dividend and dates
Earnings Date
September 14, 2026
Avg Volume
236.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HYFT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−27.47%
2025+341.75%
2024−75.91%
2023−67.18%
2022−2.80%
2021−64.15%
2020+579.55%
2019−13.89%
2018+9.42%
2017+46600.00%
2016 (partial year)−66.67%

As of September 4, 2026.

HYFT Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2025$15.56M−$13.95M−89.7%
2024$10.63M−$30.23M−284.5%
2023$10.28M−$26.12M−254.1%
2022$20.67M−$26.56M−128.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$15.56M$9.15M−$14.90M−$13.95M−89.7%
2024$10.63M$5.73M−$15.59M−$30.23M−284.5%
2023$10.28M$4.09M−$17.21M−$26.12M−254.1%
2022$20.67M$11.56M−$25.61M−$26.56M−128.5%

Annual figures as reported, in the company's reporting currency. As of April 30, 2026.

HYFT Valuation vs Biotechnology Median

Median of 656 stocks
MetricHYFTBiotechnology medianvs median
P/S ratio3.9915.260.3x the median
Profit margin−89.66%0.00%89.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

MindWalk Holdings Corp. (HYFT) carries a market capitalisation of $62.02M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 74 employees.

HYFT last closed at $1.32 on September 4, 2026. That is −$0.01 (−0.75%) against the previous close. The 52-week range on file runs from $0.99 to $2.99. The latest close sits 33.33% above that 52-week low.

Financial Health

In fiscal 2025, MindWalk Holdings Corp. reported revenue of $15.56M. Against the prior fiscal year total of $10.63M, that is a change of +46.41%. The same year closed with a net loss of $13.95M. Profit margin runs at −89.66%. That is 89.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.24.

Across the 4 fiscal years on file, revenue moves from $20.67M in 2022 to $15.56M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 3.99 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.83. Daily returns over the trailing 10 years annualize to a volatility of 27,676.93%. The trailing one-year price return is −33.67%. Across 10 years the annualized return works out at +74.65%.

Growth & Income

No dividend is on file for HYFT.

Across the complete calendar years on file, 2017 returned +46,600.00% and 2024 returned −75.91%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −27.47%.

Peer Comparison

MindWalk Holdings Corp. (HYFT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MindWalk Holdings Corp. HYFT $62.02M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MindWalk Holdings Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MindWalk Holdings Corp.

MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.

Visit website →